Oncolytics Biotech is trading 5.02% up at $0.57 on October 15, 2026, following its GOBLET enrollment update; available reporting does not explicitly attribute the gain to it. - The October 14 update said enrollment was complete; final Cohort 4 results are expected in Q4 2026, with initial Cohort 5 results expected in the first half of 2027. - XBI rose 2.20% during the regular session, but mixed market context does not establish a broad-market explanation. No reliable volume figure was found.